Great American Cookies Has a Zest for Summer with All-New Lemon Cookie
June 17, 2024 09:00 ET
|
FAT Brands Inc.
Lemon Cookie, Blueberry Muffin Cookie and Strawberry Crinkle Cookie Make for Picnic Perfect Pairing LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Great American Cookies, the Original Cookie Cake...
LPL Financial Welcomes Russell Wealth Partners
June 17, 2024 09:00 ET
|
LPL Financial Holdings, Inc.
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq: LPLA) announced today that financial advisor Tom Russell, CFP®, and his sons Brian Russell and Charles Russell have joined...
Buy Now Pay Later Market Projected to Surpass USD 49.41 billion by 2031, Witnessing 26.1% CAGR Growth
June 17, 2024 09:00 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, June 17, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Global Buy Now Pay Later Market will attain a value of USD 49.41 Billion by 2031, with a CAGR of 26.1% over the forecast...
Digerati Technologies Reports Revenue of $7.430 Million for Third Quarter Fiscal Year 2024
June 17, 2024 09:00 ET
|
Digerati Technologies
- Non-GAAP Adjusted EBITDA – OPCO(1) of $0.784 Million – SAN ANTONIO, June 17, 2024 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc. (OTCQB: DTGI) ("Digerati" or the "Company"), a provider of cloud...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
iTeos und GSK starten Phase-III-Studie GALAXIES Lung-301 zur Untersuchung von Belrestotug und Dostarlimab bei zuvor unbehandeltem, inoperablem, lokal fortgeschrittenem/metastasiertem, PD-L1-selektiertem, nicht-kleinzelligem Lungenkrebs
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Massachusetts, und GOSSELIES, Belgien, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) („iTeos“), ein im klinischen Stadium tätiges Biopharmazie-Unternehmen, das...
Début de l’étude GALAXIES Lung-301 de Phase III à l’initiative conjointe d’iTeos et de GSK, visant à évaluer le doublet belrestotug + dostarlimab chez les patients atteints d’un cancer du poumon non à petites cellules PD-L1-positif, localement avancé ou métastatique, non résécable, non préalablement traité
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, État du Massachusetts et GOSSELIES, Belgique, 17 juin 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), ci-après « iTeos », une société biopharmaceutique au stade...
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Flip Classroom Market to Grow at CAGR of 15.50% through 2033, The Brainy Insights
June 17, 2024 09:00 ET
|
The Brainy Insights
Newark, June 17, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 2.5 Billion Flip Classroom market will reach USD 10.56 Billion by 2033. Flexible and accessible learning growth...
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
June 17, 2024 09:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...